2010
Incanthera established as a spin-out from the University of Bradford Institute of Cancer Therapeutics (ICT).
2011
Receives first institutional investment alongside assignment of intellectual property and enters into the Pipeline Agreement with ICT.
2012
Receives further institutional investment for the development of a revolutionary new cancer therapy arising from ICT. The Company uses the investment to complete several pre-clinical studies adding significant value to its rapidly increasing data package.
2013
Launches a partnership with global investment group Technomark Life Sciences. The two businesses begin to work together to prepare ICT2588 Incanthera’s revolutionary treatment for solid tumours – for clinical trials.
2014
Acquires Onco-NX, an anticancer drug discovery Company. Begins an advanced preclinical
programme for ICT03-Es5. Granted a patent in the US and Japan for ICT01-2588.
2015
Completes a successful fundraise of £1.3m., acquires a new drug programme through Spear Therapeutics Limited and acquires further technology through the Pipeline Agreement.
2016
Incanthera is granted patents in Great Britain and the US for its programme ICT03-EsS and acquires further technology through the Pipeline Deal.
2017
Incanthera signs first commercial deal for the Company’s lead asset, ICT01-2588.
2018
Incanthera signs extension to the unique pipeline deal with the ICT for a further ten years.
Acquisition of technology for innovative topical application for solar keratosis and melanoma, Sol.
2020
Incanthera announces successful flotation on London’s AQSE Growth Market.
Major progress with Sol achieved - read more
2023
Incanthera announces commercial deal for its luxury skincare brand, Skin + CELL, with Marionnaud (Switzerland), part of AS Watson Group, the world’s largest health and beauty retailer with over 16,000 stores globally.